Results 121 to 130 of about 207,835 (296)

Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade

Molecular Oncology, EarlyView.
Rolig, Peng, and colleagues have shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. They found that response to immunotherapy with anti‐PD1 + anti‐LAG3 was associated with reprogramming of canonically suppressive CD4+ regulatory T cells to an inflammatory state.
Tullia C. Bruno, Anthony R. Cillo
wiley   +1 more source

Use of Water-Soluble β-Cyclodextrin Derivatives as Carriers of Anti-inflammatory Drug Biphenylylacetic Acid in Rectal Delivery

, 1992
Hidetoshi Arima, Takashi Kondo, Tetsumi Irie, Fumitoshi Hirayama, Kaneto Uekama, Tatsuaki Miyaji, Yoshimasa Inoue   +6 more
openalex   +2 more sources

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

Polysaccharides as Drug Carriers: Biodisposition of Fluorescein-Labeled Dextrans in Mice.

, 1997
Yoshiharu Kaneo, Tomochika Uemura, Tetsuro Tanaka, Satoshi Kanoh   +3 more
openalex   +2 more sources

H+/amino acid transporter 1 (PAT1) is the imino acid carrier: An intestinal nutrient/drug transporter in human and rat [PDF]

, 2004
Catriona M. H. Anderson, Danielle S. Grenade, Michael Boll, Martin Foltz, Katherine A. Wake, David J. Kennedy, Lars Kristian Munck, Seiji Miyauchi, Peter M. Taylor, F C Campbell, B. G. Munck, Hannelore Daniel, Vadivel Ganapathy, David T. Thwaites   +13 more
openalex   +1 more source

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

Molecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez, Asieh Naderi, Kim‐Tuyen Huynh‐Dam, Vitali Sikirzhytski, Ioulia Chatzistamou, Hippokratis Kiaris   +5 more
wiley   +1 more source

Antiviral and Antibacterial Sulfated Polysaccharide-Chitosan Nanocomposite Particles as a Drug Carrier. [PDF]

Molecules, 2023
Yin AY, Xu J, Yang CS, Hsu SH.
europepmc   +1 more source

Passive targeting with liposomal drug carriers.

, 1999
Kazuo Maruyama
openalex   +2 more sources

Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis [PDF]

, 2004
Anjali Sharma, Sadhna Sharma, G. K. Khuller   +2 more
openalex   +1 more source

Raphin‐1 mediates the survival and sensitivity to radiation of pediatric‐type diffuse high‐grade glioma via phosphorylated eukaryotic initiation factor 2α‐dependent and ‐independent processes

Molecular Oncology, EarlyView.
Raphin‐1 reduces the survival of PED‐DHGG cells and enhances their radiation sensitivity through both PeIF2α‐dependent and PeIF2α‐independent mechanisms. Raphin‐1 sustains elevated levels of PeIF2α, contributing to its PeIF2α‐dependent effects. Additionally, raphin‐1 interacts with CReP to mediate a separate radiosensitizing pathway that operates ...
Karin Eytan, Moshe Leitner, Amos Toren, Shoshana Paglin, Michal Yalon   +4 more
wiley   +1 more source